Article Text

Download PDFPDF

Correspondence
Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study
Free
  1. Raimon Sanmarti,
  2. Jose Inciarte-Mundo,
  3. Paula Estrada-Alarcon,
  4. Maria Garcia-Manrique,
  5. Javier Narvaez,
  6. Jesus Rodriguez-Moreno,
  7. Antoni Gomez-Centeno,
  8. Mariona Pascal,
  9. Jordi Yagüe
  1. Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain
  1. Correspondence to Dr Raimon Sanmarti, Rheumatology Department, Hopsital Clinic de Barcelona, Villarroel 170, Barcelona 08036, Spain; sanmarti{at}clinic.cat

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the paper by Chen et al1 analysing the relationship between therapeutic response to adalimumab and etanercept and serum drug trough levels in 70 patients with rheumatoid arthritis (RA). The authors confirmed a positive association between drug levels and European League Against Rheumatism (EULAR) response. Good responders showed significantly higher drug levels than moderate or poor responders, in line with other studies.2 ,3 The authors calculated (receiver operating characteristic curves) highly sensitive and specific cut-off trough levels of response (1.274 and 1.046 μg/mL for therapeutic response to adalimumab and 1.242 and 0.800 μg/mL for etanercept at 6 and 12 months, respectively). The study also highlights the importance of establishing an optimal cut-off for the …

View Full Text

Linked Articles